BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33678791)

  • 21. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab.
    Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C
    Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271
    [No Abstract]   [Full Text] [Related]  

  • 22. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.
    Campredon P; Mouly C; Lusque A; Bigay-Game L; Bousquet E; Mazières J; Caron P
    Presse Med; 2019 Apr; 48(4):e199-e207. PubMed ID: 31005502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy.
    Narahira A; Yanagi T; Cho KY; Nakamura A; Miyoshi H; Hata H; Imafuku K; Kitamura S; Shimizu H
    J Dermatol; 2017 Apr; 44(4):e70. PubMed ID: 27608187
    [No Abstract]   [Full Text] [Related]  

  • 24. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
    Nomura M; Oze I; Masuishi T; Yokota T; Satake H; Iwasawa S; Kato K; Andoh M
    Int J Clin Oncol; 2020 May; 25(5):972-977. PubMed ID: 31938955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review.
    Iglesias P; Sánchez JC; Díez JJ
    Pituitary; 2021 Aug; 24(4):630-643. PubMed ID: 33761049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
    Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
    JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A Case of Isolated ACTH Deficiency Induced by Nivolumab in a Patient with Gastric Cancer Metastasis of the Peritoneum].
    Mashita N; Otake K; Nonogaki A; Saito H; Nakamura M; Yamanaka M; Tobinaga J; Ishigure K
    Gan To Kagaku Ryoho; 2019 Dec; 46(12):1879-1882. PubMed ID: 31879407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
    Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
    JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
    [No Abstract]   [Full Text] [Related]  

  • 29. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
    Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
    Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab-induced thyroid dysfunction in patients with lung cancer.
    Ramos-Levi AM; Rogado J; Sanchez-Torres JM; Colomer R; Marazuela M
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Jan; 66(1):26-34. PubMed ID: 29910159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
    Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
    Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
    Korman AM; Tyler KH; Kaffenberger BH
    Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
    [No Abstract]   [Full Text] [Related]  

  • 36. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract]   [Full Text] [Related]  

  • 38. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.
    Xu W; Moor RJ; Walpole ET; Atkinson VG
    Melanoma Res; 2019 Jun; 29(3):333-337. PubMed ID: 30730328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
    Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.